Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Capital Employed (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Capital Employed for 5 consecutive years, with 0.61% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 48.0% year-over-year to 0.61%; the TTM value through Mar 2026 reached 0.61%, up 48.0%, while the annual FY2025 figure was 0.86%, 4.0% up from the prior year.
  • Return on Capital Employed hit 0.61% in Q1 2026 for Phathom Pharmaceuticals, up from 1.36% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.58% in Q4 2023 and bottomed at 1.49% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.98%, with a median of 0.97% recorded in 2024.
  • Year-over-year, Return on Capital Employed soared 57bps in 2024 and then crashed -62bps in 2025.
  • Phathom Pharmaceuticals' Return on Capital Employed stood at 1.1% in 2022, then skyrocketed by 47bps to 0.58% in 2023, then plummeted by -60bps to 0.93% in 2024, then plummeted by -46bps to 1.36% in 2025, then skyrocketed by 55bps to 0.61% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.61%, 1.36%, and 1.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.